Kalaris Therapeutics, Inc. GAAP EPS of -$0.64
Source: SeekingAlpha
2025-11-12 10:10:32 ET
More on Kalaris Therapeutics, Inc.
- Seeking Alpha’s Quant Rating on Kalaris Therapeutics, Inc.
- Historical earnings data for Kalaris Therapeutics, Inc.
- Financial information for Kalaris Therapeutics, Inc.
Read the full article on Seeking Alpha
For further details see:
Kalaris Therapeutics, Inc. GAAP EPS of -$0.64
Kalaris Therapeutics Inc.
NASDAQ: KLRS
KLRS Trading
6.05% G/L:
$9.81 Last:
15,628 Volume:
$9.46 Open:
KLRS Latest News
January 28, 2026 04:05:00 pm
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
December 17, 2025 05:59:02 pm
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
December 17, 2025 04:01:00 pm
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
KLRS Stock Data
$187,398,228
4,677,475
1.26%
26
N/A
Biotechnology & Life Sciences
Healthcare
US
Berkeley Heights
